Logotype for Navin Fluorine International Limited

Navin Fluorine International (532504) Q4 25/26 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Navin Fluorine International Limited

Q4 25/26 earnings summary

29 Apr, 2026

Executive summary

  • Achieved six consecutive quarters of revenue and profitability growth, with FY26 consolidated sales reaching ₹3,379.19 crore, up 41% year-over-year, and operating EBITDA of ₹1,081.7 crore, up 103% year-over-year.

  • Declared a final dividend of ₹8.60 per share (430% of face value), following an interim dividend of ₹6.50 per share, reflecting strong performance and confidence in future growth.

  • All business segments—HPP, Specialty Chemicals, and CDMO—delivered strong revenue growth, with CDMO leading at 61% YoY in Q4.

  • Annual audited standalone and consolidated financial results for FY26 were approved with unmodified audit opinions.

  • Board approved re-appointments of key directors and set record date for dividend eligibility as June 12, 2026.

Financial highlights

  • Q4 FY26 consolidated revenue: ₹937.7 crore, up 34% year-on-year; Q4 operating EBITDA: ₹321.2 crore, up 80% year-on-year, with margin expansion to 34.2%.

  • FY26 consolidated revenue: ₹3,379.19 crore, up from ₹2,393.11 crore in FY25; FY26 operating EBITDA: ₹1,081.7 crore, margin at 32.6%, up 992 bps.

  • FY26 profit after tax: ₹663.55 crore, up from ₹288.58 crore; Q4 profit after tax: ₹212.6 crore, up 124% year-on-year.

  • Net working capital days improved to 74 from 90; guidance for 75-80 days going forward.

  • Exceptional item gain of ₹13.72 crore in Q4 FY26 due to reversal of excess Labour Code provision.

Outlook and guidance

  • CapEx projects underway in HFC, MPP, Advanced Materials, and KMOS, with total planned investments exceeding ₹430 crore, funded mainly by internal accruals.

  • Commissioning and ramp-up of additional HFC capacities (32 MPP) and KMOS project expected in the coming year.

  • Margin guidance maintained at ~30% for FY27, with expected fluctuations of 1-2%.

  • Double-digit revenue growth anticipated for specialty chemicals and HPP segments in FY27.

  • Strong order visibility and positive outlook across all business segments, with new product launches and capacity expansions scheduled for FY27.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more